Contaminated Eye Drops Spark Crisis: What You Need to Know About the Deadly Outbreak
Explore the multi-state outbreak linked to contaminated over-the-counter eye drops, the federal investigation, and the serious health consequences, including vi
By Foodie Pundit Newsroom - Published - Updated - Section: Food Safety

Key points
- Over-the-counter eye drops can pose serious health risks if contaminated, as highlighted by a multi-state outbreak of a drug-resistant bacteria.
- The FDA's inspection report documented significant safety observations at the manufacturing facility in India, including issues with sterility and testing, which were identified as contributing factors to the contamination.
- The outbreak has brought to light potential gaps in the regulation of over-the-counter drugs, especially those manufactured overseas, leading to discussions about stricter oversight.
- Consumers should exercise caution, check for recalls, and immediately stop using any eye drop if they suspect a problem, as infections can lead to severe outcomes including vision loss and death.
- Legal accountability is being pursued through lawsuits against manufacturers and retailers, alleging their role in distributing the contaminated products.
A seemingly harmless purchase, a simple bottle of artificial tears, became the focus of a significant public health alert across the United States. Dozens of Americans have experienced severe infections, permanent vision loss, and in some instances, death, which have been linked to contaminated over-the-counter eye drops. This incident has brought to light vulnerabilities in the manufacturing and regulation of these common household products, leading to a federal investigation and raising urgent questions about consumer safety in a globalized supply chain.
The outbreak is associated with a highly drug-resistant strain of bacteria, Pseudomonas aeruginosa. This particular strain had not been commonly observed in the United States prior to this event. It has proven challenging to treat, being resistant to nearly all standard antibiotics, which has limited treatment options for the severe infections it causes. The Centers for Disease Control and Prevention (CDC) has played a key role in the epidemiological investigation, working to trace the infections back to their source.
As of early 2023, the CDC had identified nearly 70 individuals in over a dozen states with infections linked to the outbreak strain. The consequences have been severe. Several patients have undergone surgical removal of their eyeballs, a procedure known as enucleation.
Others have been left with permanent blindness. The infections have not been limited to the eyes; the bacteria has also been associated with respiratory and urinary tract infections, and in some tragic cases, has entered the bloodstream, leading to sepsis and death.
The trail of evidence quickly led investigators to specific products. The majority of affected patients reported using artificial tears before their symptoms began. A pattern emerged, with one brand being frequently mentioned: EzriCare Artificial Tears.
This product, along with others identified as manufactured by Global Pharma Healthcare, became a primary focus of the investigation. The products were sold online through major retailers like Amazon and in stores such as Walmart, making them widely accessible to consumers.
The initial response involved urgent warnings from the CDC and the Food and Drug Administration (FDA). In February 2023, the agencies issued a joint statement advising consumers to immediately stop using EzriCare Artificial Tears and another product, Delsam Pharma’s Artificial Tears. This directive was a critical public health measure aimed at preventing further infections while investigators worked to confirm the source of the contamination.
Global Pharma Healthcare, an India-based company, initially issued a voluntary recall of the suspected products. Subsequently, FDA inspections revealed significant issues in the conditions under which these eye drops were made. Agency inspectors who visited the company’s manufacturing facility in Tamil Nadu, India, identified a series of failures in basic safety protocols.
The FDA’s inspection report, released to the public, detailed observations regarding the company’s practices. It highlighted a lack of sterility and quality control. Investigators found "black, brown greasy-like deposits" on machinery and "peeling paint and water stains" in areas designated as clean rooms.
The report noted that the company’s process for sterilizing the bottles was identified as "deficient." Most critically, the report indicated that the company failed to use an adequate preservative in its multi-use bottles, which could create an environment conducive to bacterial growth.
One of the significant findings was the company’s reported failure to conduct proper batch testing for sterility. In one instance cited in the report, a batch of product reportedly failed sterility tests but was distributed. The FDA observed that these practices were not in adherence to established safety standards, known as Current Good Manufacturing Practice (CGMP) regulations, which contributed to the issues identified. The FDA placed the company on import alert, effectively blocking its products from entering the United States.
The bacterial strain at the heart of the outbreak, Verona Integron-mediated Metallo-beta-lactamase and Guiana Extended-Spectrum-beta-Lactamase-producing carbapenem-resistant Pseudomonas aeruginosa (VIM-GES-CRPA), is a complex medical term that describes a highly resistant pathogen. Its resistance to carbapenems, a class of powerful last-resort antibiotics, makes it exceptionally difficult to treat. The CDC’s laboratory analysis confirmed the genetic link between the bacteria found in patients and the bacteria found in open bottles of EzriCare eye drops collected from homes across the country.
What began with a focus on one manufacturer soon revealed broader issues potentially impacting the over-the-counter eye drop market. As the FDA intensified its scrutiny of imported eye care products, it identified similar sterility problems at other manufacturing plants. This led to a series of recalls from different companies and brands, which could create confusion and concern among consumers.
In the months that followed the initial EzriCare recall, the FDA issued warnings and requested recalls for more than two dozen other over-the-counter eye drop products. Brands such as Clear Eyes, CVS Health, Rite Aid, and Target’s Up & Up were implicated, not necessarily because they were contaminated with the same bacteria, but because they were produced in facilities where conditions could lead to contamination. The FDA warned that products made in unsanitary environments had a high potential for causing eye infections and vision loss.
The reasons for these subsequent recalls varied but often centered on a lack of preservatives in preservative-free formulas, which are packaged in a way that is intended to maintain sterility but can become compromised if manufacturing standards are not met. The FDA found cracks in sealing surfaces and other defects that were observed to compromise the sterility of the products before they reached the consumer.
The number of recalls has been substantial. It highlights potential gaps in regulatory oversight for products classified as over-the-counter drugs. While prescription drugs undergo a rigorous pre-market approval process, many OTC products do not.
Instead, the FDA relies on a system of monographs and CGMP regulations, with inspections that can be infrequent, especially for foreign facilities. The COVID-19 pandemic further complicated this, reportedly leading to a backlog of international inspections.
Behind the clinical-sounding acronyms and regulatory reports are stories of profound human suffering. Individuals who used a common remedy for dry eyes found their lives significantly impacted. Teresa C.
, a resident of Florida, shared with reporters that she had to have her left eye removed following an infection that doctors traced back to her use of EzriCare drops. Her case is one of many that have resulted in lawsuits against manufacturers and retailers.
Class-action lawsuits have been filed across the country, alleging that Global Pharma Healthcare was negligent in its manufacturing processes and that retailers like Walmart and Amazon failed to ensure the safety of the products they sell. These legal actions seek to hold the companies accountable and to compensate victims for their medical bills, lost wages, and the immense pain and suffering they have endured.
The emotional and financial toll on the victims has been immense. Many have faced a harrowing series of surgeries, long hospital stays, and a demanding regimen of powerful antibiotics with debilitating side effects. The loss of vision is a life-altering event, affecting a person’s ability to work, to care for themselves, and to engage in daily activities. This event has served as a powerful reminder of the trust consumers place in manufacturers every day and the significant consequences when that trust is compromised.
The contaminated eye drop crisis has prompted a reevaluation at the FDA and across the pharmaceutical industry. It has put a spotlight on the challenges of regulating a global supply chain where components and finished products cross multiple borders before reaching the consumer. The heavy reliance on foreign manufacturers for generic and over-the-counter drugs means that the FDA
Sources and methodology
Reported from the public datasets below.
More from the Foodie Pundit Newsroom
- Is Gainesville The Next Big Acai Town?
- Mills 50 Is Getting A Bunch Of New Restaurants
- Botswana Farmers Adopt Climate Technology to Protect Crop Yields and Restaurant Supply Chains
- Medical Studies Suggest GLP-1 Side Effects May Prompt Restaurant Adaptation to Changing Consumer Habits
- Vigorous Legal Fight Erupts Over Luxury Resort's Food and Beverage Trademarks